Read on Twitter
Just posted in @JAMA_current!
Randomized controlled #remdesivir trial of hospitalized patients with moderate #COVID19 pneumonia—those with with infiltrates on imaging with O2 Sats >94% on room-air.
#hungergames feel: may the odds be ever in your favor!
https://jamanetwork.com/journals/jama/article-abstract/2769871
Randomized controlled #remdesivir trial of hospitalized patients with moderate #COVID19 pneumonia—those with with infiltrates on imaging with O2 Sats >94% on room-air.
#hungergames feel: may the odds be ever in your favor!
https://jamanetwork.com/journals/jama/article-abstract/2769871
People are scratching their heads on why the odds were better for the 5-day #remdesivir group and not for the 10-day group.
I think the results were influenced by the open-label design and the fact that discharge was the best endpoint in the scale.
I think the results were influenced by the open-label design and the fact that discharge was the best endpoint in the scale.
As you can see above, the majority of patients received the maximum number of days allowed by the treatment group, 76% for the 5-day #remdesivir group, 38% for the 10-day group.
In addition, there were peak of discharges on day 6 and 11 in those groups, respectively.
In addition, there were peak of discharges on day 6 and 11 in those groups, respectively.
The distribution of discharges for the 10-day #remdesivir group is ~bimodal with peaks on days 4 and 11.
The OR for improvement was 1.31 compared to standard-care, but was not significant. because of this distribution, proportional odds was not met, so OR could not be reported.
The OR for improvement was 1.31 compared to standard-care, but was not significant. because of this distribution, proportional odds was not met, so OR could not be reported.
